Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2026Journal of Lipid and AtherosclerosisOpen Access

Olezarsen and other emerging therapies targeting APOC3 and ANGPTL3 effectively lower triglycerides and provide new treatment options for FCS.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

In familial chylomicronemia syndrome, traditional triglyceride-lowering medications are ineffective, leaving patients dependent on strict low-fat diets.

Do emerging targeted treatments reduce triglycerides in patients with familial chylomicronemia syndrome?

Design

Narrative review

Authors

MNMeghashree NKBKushal C BDSD R Shivaraj

Discussion

Loading...

Member takes

Overview

May expand FCS options; leaves open randomized confirmation of clinical outcomes.

Structured PICO

Do emerging targeted treatments reduce triglycerides in patients with familial chylomicronemia syndrome?

P
Population
Patients with familial chylomicronemia syndrome (FCS) and related triglyceride disorders
I
Intervention
Emerging non-LPL-based therapies including olezarsen, ANGPTL3 inhibitors, RNA interference therapies, gene therapy, CRISPR-Cas9, and plasmapheresis
O
Outcome
Triglyceride reduction and safetysurrogate

Innovative therapies targeting APOC3, ANGPTL3, or liver-specific genes are transforming the management of familial chylomicronemia syndrome.

Cite This Study

N et al. (2026) studied this question.

synapsesocial.com/papers/6a1e80637f6e8bbb2369025chttps://doi.org/10.12997/jla.2026.15.1.72
View Full Paper
Ask AI
Bookmark
Share